On the one hand, in vivo and clinical evidence support that targeting mutant BRAF increases antigen expression [86], MHCs class I and II [87] and PDL1 [86] expression in melanoma cells as well as an increase in CD8+ T-cell infiltrate in tumors of patients [88]. This evidence concerns the gene CD274 and melanoma.